Trial record 1 of 1 for:
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. (CABOTHYROID)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05660954 |
|
Recruitment Status :
Recruiting
First Posted : December 21, 2022
Last Update Posted : August 4, 2023
|
Sponsor:
Grupo Espanol de Tumores Neuroendocrinos
Collaborators:
Ipsen
MFAR
Information provided by (Responsible Party):
Grupo Espanol de Tumores Neuroendocrinos
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | June 2025 |
| Estimated Study Completion Date : | June 2025 |